Skip to main content

Comparative Study of the Effect of Single-Dose Treatment with Butyrate or L-Glutamine on Secretion of Gut Hormones in Type 2 Diabetes Subjects (Study Number IFD-101-CL3-001)

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
May 14, 2013
Award amount: 
Organization name: 
BioKier, Inc.
Principal Investigator: 
Nolan, Roger D.
Grant program category: 
Business Financing
Grant program name: 
Strategic Growth Loan
Research Triangle

The purpose of this study is to determine in type 2 diabetes patients if butyrate and L-glutamine cause the secretion of gut hormones when delivered in a single dose to the colon. This is important because gut hormones, in particular GLP-1, secreted from the colon are important for the regulation of blood glucose and the secretion of these hormones is deficient in type 2 diabetes. The pharmaceutical industry has been exploring ways to restore the levels of gut hormones in diabetes patients. BioKier has identified two natural compounds, L-glutamine and butyrate, that have the potential to restore the secretion of the hormones in diabetes patients. Successful development of one of these compounds in a pill would be a major advancement in the treatment of this growing disease.

Fiscal year: